Mometasone Furoate Patent Expiration

1. Asmanex Hfa patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5889015 ORGANON LLC Use of mometasone furoate for treating lower airway passage and lung diseases
Jan, 2014

(10 years ago)

US6365581 ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jan, 2014

(10 years ago)

US6057307 ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jan, 2014

(10 years ago)

US6057307

(Pediatric)

ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jul, 2014

(9 years ago)

US6365581

(Pediatric)

ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jul, 2014

(9 years ago)

US5889015

(Pediatric)

ORGANON LLC Use of mometasone furoate for treating lower airway passage and lung diseases
Jul, 2014

(9 years ago)

US6068832 ORGANON LLC Chlorofluorocarbon-free mometasone furoate aerosol formulations
Aug, 2017

(6 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Strength(NS) Aug 12, 2022
Pediatric Exclusivity(PED) Feb 12, 2023

Market Authorisation Date: 12 August, 2019

Treatment: Treatment of asthma

Dosage: AEROSOL, METERED

More Information on Dosage

ASMANEX HFA family patents

Family Patents

2. Asmanex Twisthaler patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5394868

(Pediatric)

ORGANON LLC Inhalation device for powdered medicaments
Dec, 2012

(11 years ago)

US5889015 ORGANON LLC Use of mometasone furoate for treating lower airway passage and lung diseases
Jan, 2014

(10 years ago)

US6365581 ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jan, 2014

(10 years ago)

US6057307 ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jan, 2014

(10 years ago)

US6949532 ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jan, 2014

(10 years ago)

US6677322 ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jan, 2014

(10 years ago)

US5889015

(Pediatric)

ORGANON LLC Use of mometasone furoate for treating lower airway passage and lung diseases
Jul, 2014

(9 years ago)

US6949532

(Pediatric)

ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jul, 2014

(9 years ago)

US6057307

(Pediatric)

ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jul, 2014

(9 years ago)

US6677322

(Pediatric)

ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jul, 2014

(9 years ago)

US6365581

(Pediatric)

ORGANON LLC Use of mometasone furoate for treating airway passage and lung diseases
Jul, 2014

(9 years ago)

US5687710 ORGANON LLC Inhaler for powdered medications having spiral deagglomeration chamber
Nov, 2014

(9 years ago)

US5687710

(Pediatric)

ORGANON LLC Inhaler for powdered medications having spiral deagglomeration chamber
May, 2015

(9 years ago)

US5829434 ORGANON LLC Inhaler for powdered medications
Nov, 2015

(8 years ago)

US5829434

(Pediatric)

ORGANON LLC Inhaler for powdered medications
May, 2016

(8 years ago)

US6240918 ORGANON LLC Powdered medication inhaler
Feb, 2017

(7 years ago)

US6240918

(Pediatric)

ORGANON LLC Powdered medication inhaler
Aug, 2017

(6 years ago)

US8173172 ORGANON LLC Preparation of powder agglomerates
Mar, 2018

(6 years ago)

US6503537 ORGANON LLC Preparation of powder agglomerates
Mar, 2018

(6 years ago)

US6503537

(Pediatric)

ORGANON LLC Preparation of powder agglomerates
Sep, 2018

(5 years ago)

US8173172

(Pediatric)

ORGANON LLC Preparation of powder agglomerates
Sep, 2018

(5 years ago)




Market Authorisation Date: 01 February, 2008

Treatment: Treatment of asthma

Dosage: POWDER

More Information on Dosage

ASMANEX TWISTHALER family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Nasonex patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6723713 ORGANON LLC Use of mometasone furoate for treating upper airway diseases
Jan, 2014

(10 years ago)

US5837699 ORGANON LLC Use of mometasone furoate for treating upper airway passage diseases
Jan, 2014

(10 years ago)

US5837699

(Pediatric)

ORGANON LLC Use of mometasone furoate for treating upper airway passage diseases
Jul, 2014

(9 years ago)

US6723713

(Pediatric)

ORGANON LLC Use of mometasone furoate for treating upper airway diseases
Jul, 2014

(9 years ago)

US6127353 ORGANON LLC Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
Oct, 2017

(6 years ago)

US6127353

(Pediatric)

ORGANON LLC Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
Apr, 2018

(6 years ago)




Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-626) May 26, 2013
M(M-99) Jan 19, 2014

Market Authorisation Date: 01 October, 1997

Treatment: Allergic rhinitis or nasal polyps

Dosage: SPRAY, METERED

How can I launch a generic of NASONEX before it's drug patent expiration?
More Information on Dosage

NASONEX family patents

Family Patents

4. Sinuva patent expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8109918 INTERSECT ENT INC Sinus delivery of sustained release therapeutics
Mar, 2024

(4 months ago)

US7951130 INTERSECT ENT INC Sinus delivery of sustained release therapeutics
Mar, 2024

(4 months ago)

US7662141 INTERSECT ENT INC Sinus delivery of sustained release therapeutics
Mar, 2024

(4 months ago)

US7713255 INTERSECT ENT INC Sinus delivery of sustained release therapeutics
Mar, 2024

(4 months ago)

US7951131 INTERSECT ENT INC Sinus delivery of sustained release therapeutics
Mar, 2024

(4 months ago)

US7951133 INTERSECT ENT INC Sinus delivery of sustained release therapeutics
Mar, 2024

(4 months ago)

US9585681 INTERSECT ENT INC Device and methods for treating paranasal sinus conditions
Apr, 2026

(1 year, 8 months from now)

US7544192 INTERSECT ENT INC Sinus delivery of sustained release therapeutics
Nov, 2026

(2 years from now)

US8025635 INTERSECT ENT INC Device and methods for treating paranasal sinus conditions
Jun, 2027

(2 years from now)

US10357640 INTERSECT ENT INC Expandable devices and methods for treating a nasal or sinus condition
Oct, 2031

(7 years from now)

US8763222 INTERSECT ENT INC Methods and devices for crimping self-expanding devices
Feb, 2032

(7 years from now)

US10406332 INTERSECT ENT INC Systems, devices, and method for treating a sinus condition
Mar, 2034

(9 years from now)

US10232152 INTERSECT ENT INC Systems, devices, and method for treating a sinus condition
Nov, 2034

(10 years from now)




Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 08, 2020

Market Authorisation Date: 08 December, 2017

Treatment: Treatment of nasal polyps in patients >=18 years of age who have had ethmoid sinus surgery using a corticosteroid-eluting (mometasone furoate) implant

Dosage: IMPLANT

More Information on Dosage

SINUVA family patents

Family Patents